Inozyme Pharma

INZY

Biotech

Health Care

Pharma

Country

US

Industry

Health Care

Market Cap

Micro Cap

Num. Employees

56

IPO Date

Jul 24, 2020

Create Alert

INZY

Country

US

Industry

Health Care

Biotech

Health Care

+1

Create Alert

Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. The company is headquartered in Boston, Massachusetts and currently employs 56 full-time employees. The company went IPO on 2020-07-24. The firm is focused on developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue and skeleton. The firm is also focused on developing a novel therapy to treat the rare genetic diseases of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) and ATP-Binding Cassette in the C6 family (ABCC6) Deficiencies. The Company’s lead product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies. Its INZ-701 is in Phase 1/2 clinical trials for the treatment of ENPP1 Deficiency and ABCC6 Deficiency. INZ-701 is designed to increase circulating levels of plasma pyrophosphate (PPi), and adenosine.